Protalix (PLX) Stock Profit Swing Sharpens Focus On Elfabrio Reliance

Protalix BioTherapeutics shares jumped 7.8% to US$2.62 into the close, and that move captures only part of the story. The stock came into this print already on a strong run over the past three months. Today’s reaction, however, appears to lean more on emotion than on new information.

The focus is on margin and profitability. Q2 net income reached US$3.8m with earnings per share of US$0.05, supported by US$19.9m in revenue and a cash balance of about US$40.7m with no debt. The market appears to be responding to the overall profit profile and balance sheet strength rather than to any single line item.

Is Protalix BioTherapeutics trading at a genuine discount after this profit swing, or is the low P/E sending a false signal? See how the current price compares to the implied fair value in our valuation analysis for Protalix BioTherapeutics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$19.9m vs. US$15.7m (up about 27%)
• Net Income, Q2 2026 vs. Q2 2025: US$3.8m vs. US$0.16m (very large increase)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.05 vs. US$0.00 (rounded, moved from roughly breakeven to a clear profit per share)
• Net Profit Margin, Trailing 12 Months vs. Prior Year: 20.1% vs. 6.5% (margin materially higher)

Prefer clean charts instead of wading through dense earnings tables and raw figures? See Protalix BioTherapeutics' full financial picture with a visual breakdown of its valuation in the company report for Protalix BioTherapeutics.

Protalix bull case hinges on Elfabrio momentum

Bulls argue Protalix BioTherapeutics is turning Elfabrio and the Chiesi partnership into a durable profit engine with improving margins and a growing Fabry footprint. Q2 revenue of US$19.9m and net income of US$3.8m, together with a 20.1% trailing net margin, show that commercial supply and manufacturing scale are already supporting profitability. The jump in selling goods revenue to US$19.8m, mainly from higher Chiesi purchases, lines up with the story of deeper market penetration following Europe and South Korea approvals. Lower reported R&D spending of US$4.4m, helped by the R&D law grant, and a clean balance sheet with US$40.7m cash and no debt give the company room to fund PRX-115 and rare renal programs. Guidance reaffirmation and management’s confidence in long term value creation indicate execution is broadly tracking the bullish roadmap.

Bear case tests Elfabrio reliance and revenue lumpiness

The bear argument centers on heavy reliance on Elfabrio, partner control over commercialization and volatile revenue. Q2 results partly validate these concerns. Management again highlighted that Chiesi ordering and inventory decisions create lumpy quarterly revenue and urged investors to judge performance on a full year basis. That is a direct acknowledgment of limited control over demand timing. H1 2026 revenue of US$53.6m is flattered by the previously reported US$25m milestone from Chiesi rather than pure recurring product sales. This mix adds uncertainty to future revenue run rate. The pipeline led by PRX-115 still sits in mid stage development with Phase 2 top line data only expected in H2 2027 and enrollment not finishing until year end 2026. Until those milestones are reached, Protalix remains concentrated in one commercial asset and one partner, which keeps the core bear concern intact.

Compare Protalix BioTherapeutics' profit swing and Elfabrio led growth story with how the Street is recalibrating its expectations right now. See the consensus price target analysis for Protalix BioTherapeutics

Take Control of Your Next Move

If Protalix BioTherapeutics' profit swing and Elfabrio driven story have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter to your holdings. For a longer term view, tap into the Community to see how other investors are thinking about Protalix BioTherapeutics and similar stocks. Spot potential catalysts and risks earlier so you can stay ahead of the market rather than reacting to it.

Seeking Alternatives Beyond Protalix BioTherapeutics

Fresh ideas move first when momentum starts building and prices have not yet flown out of reach. Scan under the radar for now, before the crowd catches up, and act now.

• Spot income workhorses early and review 9 dividend fortresses that could help keep cash flow coming in while prices are still settling and yields remain compelling.
• Front run the next quality shift and size up the 20 high quality undiscovered gems hiding strong fundamentals before steady coverage arrives and the best entry points get crowded.
• Ride the infrastructure backbone of AI and assess the 56 AI infrastructure stocks supporting growth in data centers and chips while these picks are still dropping fresh into view.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com